Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robbin, M. L.
Right arrow Articles by Eisenfeld, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robbin, M. L.
Right arrow Articles by Eisenfeld, A. J.

Radiology, Vol 207, 717-722, Copyright © 1998 by Radiological Society of North America

ARTICLES

Perflenapent emulsion: a US contrast agent for diagnostic radiology-- multicenter, double-blind comparison with a placebo. EchoGen Contrast Ultrasound Study Group

ML Robbin and AJ Eisenfeld
Department of Radiology, University of Alabama, Birmingham 35233-1924, USA.

PURPOSE: To evaluate perflenapent emulsion as a contrast agent for ultrasound (US) of the liver, kidneys, and vasculature. MATERIALS AND METHODS: A randomized, double-blind, placebo-controlled, multicenter trial of 151 patients was performed. Investigators and blinded readers compared sonograms obtained after intravenous administration of perflenapent emulsion (0.05 mL/kg) and of a placebo with baseline sonograms. RESULTS: Contrast enhancement occurred in 140 of 149 patients (94%) after perflenapent administration and in 12 patients (8%) after placebo administration (P < .001). Enhancement lasted 5.0- 15.4 minutes with perflenapent and 0.1-1.7 minutes with the placebo (P < .001). Perflenapent enhanced or facilitated visualization of blood flow, abnormal structures, masses, and lesions in 138 of 147 patients (94%) versus 12 of 147 (8%) for the placebo (P < .001). Improved visualization assisted in the diagnosis in 105 of 143 perflenapent studies (73%) compared with five of 143 placebo studies (3%) (P < .001). Diagnostic information affected case management in 71 of 148 patients (48%) after perflenapent administration and in nine of 148 patients (6%) after placebo administration (P < .001). Adverse effects associated with perflenapent were few and mostly mild, occurred within 30 minutes, and resolved without treatment. CONCLUSION: Perflenapent emulsion is a safe and effective contrast agent for US of the liver, kidneys, and vasculature.


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
T. Yasu, G. W. Schmid-Schonbein, B. Cotter, and A. N. DeMaria
Flow dynamics of QW7437, a new dodecafluoropentane ultrasound contrast agent, in the microcirculation: Microvascular mechanisms for persistent tissue echo enhancement
J. Am. Coll. Cardiol., August 1, 1999; 34(2): 578 - 586.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1998 by the Radiological Society of North America.